Affymetrix Affirms 2004 Guidance
April 21 2004 - 3:36PM
PR Newswire (US)
Affymetrix Affirms 2004 Guidance Affymetrix Reiterates Full Year
Revenue and Earnings Per Share Guidance SANTA CLARA, Calif., April
21 /PRNewswire-FirstCall/ -- Affymetrix, Inc., a leader in creating
breakthrough tools that are driving the genomic revolution, today
reaffirmed its financial guidance for fiscal year 2004. The Company
reiterated its previous guidance for product and product related
revenue of $330 to $335 million for fiscal year 2004. Total revenue
for the year, which includes Perlegen, royalties and other revenue,
is projected to be $345 to $350 million. GAAP earnings per share
are projected to be approximately $0.50 for fiscal year 2004, which
includes the charge of $0.14 associated with the redemption of the
Company's 4.75% and 5% convertible subordinated notes. Affymetrix'
management team will host a conference call to review its operating
results for the first quarter of 2004 and to provide financial
guidance for the second quarter of 2004. A live webcast of the
conference call can be accessed by visiting the Investor Relations
section of the Company's website at http://www.affymetrix.com/. In
addition, investors and other interested parties can listen by
dialing domestic: 888-737-3798, international: 706-643-2578 on
April 21 at 2:00 p.m. PT. A replay of the conference call will be
available until 5:00 p.m. PT on April 28, 2004 at the following
numbers: domestic: 800-642-1687, international: 706-645-9291;
passcode for both: 6683630#. An archived webcast of the conference
call will be available under the Investor Relations section of the
Company's website at http://www.affymetrix.com/. About Affymetrix
Affymetrix is a pioneer in creating breakthrough tools that are
driving the genomic revolution. By applying the principles of
semiconductor technology to the life sciences, Affymetrix develops
and commercializes systems that enable scientists to improve the
quality of life. The Company's customers include pharmaceutical,
biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit
research institutes. Affymetrix offers an expanding portfolio of
integrated products and services, including its integrated GeneChip
platform, to address growing markets focused on understanding the
relationship between genes and human health. Additional information
on Affymetrix can be found at http://www.affymetrix.com/. All
statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements, including
Affymetrix' financial outlook for 2004, are subject to risks and
uncertainties that could cause actual results to differ materially
for Affymetrix from those projected, including, but not limited to,
risks of the Company's ability to achieve and sustain higher levels
of revenue, higher gross margins, reduced operating expenses,
market acceptance, personnel retention, uncertainties relating to
global economic weakness, the fluctuations in overall capital
spending in the academic and biotechnology sectors, changes in
government funding policies, unpredictable fluctuations in
quarterly revenues, uncertainties related to cost and pricing of
Affymetrix products, dependence on collaborative partners,
uncertainties relating to sole source suppliers, uncertainties
relating to FDA, and other regulatory approvals, competition, risks
relating to intellectual property of others and the uncertainties
of patent protection and litigation. These and other risk factors
are discussed in Affymetrix' Form 10-K for the year ended December
31, 2003 and other SEC reports, including its Quarterly Reports on
Form 10-Q for subsequent quarterly periods. Affymetrix expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Affymetrix' expectations with
regard thereto or any change in events, conditions, or
circumstances on which any such statements are based. NOTE:
Affymetrix, the Affymetrix logo and GeneChip are trademarks owned
or used by Affymetrix, Inc. CustomExpress is a trademark of
Affymetrix, Inc. DATASOURCE: Affymetrix, Inc. CONTACT: Doug
Farrell, Vice President of Investor Relations of Affymetrix, Inc.,
+1-408-731-5285 Web site: http://www.affymetrix.com/
Copyright
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024